201 related articles for article (PubMed ID: 23658488)
1. Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
Kim DH; Jeong YI; Chung CW; Kim CH; Kwak TW; Lee HM; Kang DH
Int J Nanomedicine; 2013; 8():1697-711. PubMed ID: 23658488
[TBL] [Abstract][Full Text] [Related]
2. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells.
Kwak TW; Lee HL; Song YH; Kim C; Kim J; Seo SJ; Jeong YI; Kang DH
Int J Nanomedicine; 2017; 12():7669-7680. PubMed ID: 29089762
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
Tomuleasa C; Cucuianu A; Aldea M; Berindan-Neagoe I
Int J Nanomedicine; 2013; 8():4043-4. PubMed ID: 24187496
[No Abstract] [Full Text] [Related]
5. In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
Wang Y; Molin DG; Sevrin C; Grandfils C; van den Akker NM; Gagliardi M; Knetsch ML; Delhaas T; Koole LH
Int J Pharm; 2016 Apr; 503(1-2):150-62. PubMed ID: 26965198
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma.
Xiao JB; Weng JY; Hu YY; Deng GL; Wan XJ
World J Gastroenterol; 2020 Aug; 26(31):4589-4606. PubMed ID: 32884219
[TBL] [Abstract][Full Text] [Related]
7. 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib.
Chu JH; Zhao CR; Song ZY; Wang RQ; Qin YZ; Li WB; Qu XJ
Biomed Pharmacother; 2014 Apr; 68(3):335-41. PubMed ID: 24581722
[TBL] [Abstract][Full Text] [Related]
8. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
9. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
[TBL] [Abstract][Full Text] [Related]
10. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
12. Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78.
Machihara K; Tanaka H; Hayashi Y; Murakami I; Namba T
Biochem Biophys Res Commun; 2017 Oct; 492(1):33-40. PubMed ID: 28811106
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
14. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
18. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L
Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758
[TBL] [Abstract][Full Text] [Related]
20. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
